Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:administered_by |
injection
inhalation |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Pentacarinat
gptkb:Pentamidine_isethionate |
| gptkbp:casnumber |
000000-00-0
|
| gptkbp:chemical_formula |
C23 H34 N4 O2
|
| gptkbp:class |
antifungal agent
antiprotozoal agent |
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:composed_by |
reacts with 1,3-dichloro-2-propanol
synthesized from 2,4-diaminobenzenesulfonamide |
| gptkbp:contraindication |
renal impairment
hypersensitivity to pentamidine |
| gptkbp:discovered_by |
1940s
|
| gptkbp:dissolved |
soluble in water
soluble in ethanol |
| gptkbp:form |
inhalation solution
vial for injection |
| https://www.w3.org/2000/01/rdf-schema#label |
pentamidine
|
| gptkbp:is_monitored_by |
electrolytes
renal function blood glucose levels |
| gptkbp:mechanism_of_action |
inhibits nucleic acid synthesis
|
| gptkbp:pharmacokinetics |
excreted in urine
disrupts mitochondrial function half Life is approximately 6-12 hours interferes with DNA replication |
| gptkbp:related_products |
isethionate
pentamidine dihydrochloride |
| gptkbp:route_of_administration |
intravenous
subcutaneous intramuscular |
| gptkbp:side_effect |
gptkb:anemia
dizziness fatigue headache nausea fever vomiting diarrhea rash insomnia arrhythmias chills hypoglycemia thrombocytopenia neurotoxicity hypotension hepatotoxicity nephrotoxicity pancreatitis visual disturbances |
| gptkbp:targets |
gptkb:Leishmania_species
gptkb:Pneumocystis_jirovecii |
| gptkbp:used_for |
treatment of Pneumocystis pneumonia
treatment of leishmaniasis |
| gptkbp:bfsParent |
gptkb:Trypanosoma
gptkb:pneumocystis_pneumonia gptkb:Pneumocystis_pneumonia |
| gptkbp:bfsLayer |
5
|